September 09, 2026

FDA expands sevabertinib approval in NSCLC

SOHO-01 data showed a 75% confirmed objective response rate among 69 patients without previous systemic therapy.

MDSpire News

September 08, 2026

FDA approves serial liquid biopsy testing

In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.

MDSpire News

September 04, 2026

Biomarker may flag early pregnancy risk

A protein was linked experimentally to trophoblast invasion.

MDSpire News

September 01, 2026

FDA expands essential thrombocythemia care

Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.

MDSpire News

August 28, 2026

Newborn variants may flag childhood cancer predisposition

Targeted sequencing identified cancer-risk variants in about 7% of pediatric patients who later developed early-onset solid or brain malignancies.

MDSpire News

August 19, 2026

Who develops dementia after 90?

Investigators examined associations between demographic and genetic factors and dementia risk while accounting for the competing risk of mortality.

MDSpire News

July 28, 2026

Germline Variants May Signal Early Breast Cancer Relapse

Patients carrying moderate- to high-risk breast cancer variants had poorer breast cancer–free survival, whereas polygenic risk scores did not improve prognostic stratification.

MDSpire News

July 02, 2026

FDA Expands Gene Therapy for Younger Patients

Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.

MDSpire News

June 23, 2026

HHS Announces Department-Wide Clinical Trial Initiative

Agency-wide effort targets US clinical trial timelines, enrollment, and regulatory barriers.

MDSpire News

June 08, 2026

Misdiagnosis Common in Parkinsonian Disorders

Autopsy-confirmed findings linked diagnostic errors, co-pathology, and genetic variation to distinct pathologic patterns across more than 3,300 donors with Parkinsonian disorders.

MDSpire News